Research & Innovation
Publications
Lenvatinib or Regorafenib in combination with Cdk5 inhibition – new promising therapeutic approaches for treating HCC patients
PMU Author
Petra Huber-Cantonati
All Authors
Petra Huber-Cantonati, T. Mähr, MA Ardelt, J. Pachmayr
Abstract
We are sorry. The full text is not available.